Eisai Corporation of North America, a wholly-owned subsidiary of Tokyo-based Eisai Co., Ltd., announced that the Food and Drug Administration (FDA) has approved ACIPHEX (rabeprazole sodium) 20 mg for the short-term (up to eight weeks) treatment of gastroesophageal reflux disease (GERD) in adolescents ages 12 and above. Included in the submission was a 12-week, multi-center, open-label, randomized, parallel-group study of 111 adolescent GERD patients.

More: continued here

This entry was posted on Friday, July 4th, 2008 at 2:07 pm and is filed under Acid Reflux/GERD. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.